Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.

Bio-Techne TECH continues to expand its portfolio and enter adjacent markets via acquisitions and strategic investments. Strength in international markets underscores the company’s growth potential.

Shares of Bio-Techne Corp. TECH rallied 1.82% to $54.87 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.83% to 6,795.99 and ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

Bio-Techne Corporation TECH is set to release second-quarter fiscal 2026 results on Feb. 4, before the opening bell. The life science and diagnostic product maker posted adjusted earnings per share ...

A large exercise of company stock options by Robert V Baumgartner, Director at Bio-Techne TECH was disclosed in a new SEC filing on August 27, as part of an insider exercise. What Happened: A notable ...

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ...

Bio-Techne Corp. closed 28.51% short of its 52-week high of $72.16, which the company achieved on January 22nd.